ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2609 • 2015 ACR/ARHP Annual Meeting

    The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients

    Slawomir Jeka1, Pawel Zuchowski2, Katarzyna Kolossa3, Marta Dura4 and Rafal Wojciechowski5, 1Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland, Bygdoszcz, Poland, 2Independent Section of Scientific Research Coordination and Didactic Activity, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, 3Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, 4Department of Radiology and Medical Imaging, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, 5Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Poland, Bydgoszcz, Poland

    Background/Purpose:  In course of rheumatoid arthritis (RA) ther is often impaired glucose metabolism, which leads to the development of diabetes mellitus (DM). One of the…
  • Abstract Number: 2610 • 2015 ACR/ARHP Annual Meeting

    Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients: Cardiovascular Risk, Concomitant Treatment, and Outcomes over 6 Months of Follow-up

    Boulos Haraoui1, Shahin Jamal2, Vandana Ahluwalia3, Tarang Manchanda4 and Majed M. Khraishi5, 1Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 2Vancouver Coastal Health, Vancouver, BC, Canada, 3Brampton Civic Hospital, Brampton, ON, Canada, 4Hoffmann-La Roche Canada, Mississauga, ON, Canada, 5Nexus Clinical Research, St Johns, NF, Canada

    Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs).…
  • Abstract Number: 2611 • 2015 ACR/ARHP Annual Meeting

    Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)

    Keisuke Izumi1, Misato Hashizume2, Yuko Kaneko3, Keiko Yoshimoto1 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Product Research Department, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 3Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and…
  • Abstract Number: 2612 • 2015 ACR/ARHP Annual Meeting

    Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting

    Sergio Schwartzman1, Keith Knapp2, Gary Craig3, Karen Ferguson4 and Howard Kenney5, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Arthritis Northwest, Spokane, WA, 3Discus Analytics, Inc., Spokane, WA, 4Arthritis Northwest PLLC., Spokane, WA, 5Rheumatology, Arthritis Northwest, Spokane, WA

    Background/Purpose:   A number of composite outcome measures have been validated to quantify disease activity in Rheumatoid Arthritis (RA).  Few studies have been published on the…
  • Abstract Number: 2613 • 2015 ACR/ARHP Annual Meeting

    Patient Reported Physical Capacity Correlates with Phenylalanine Serum Levels in Patients with Early Untreated Rheumatoid Arthritis

    Aulikki Kononoff1, Leena Arstila1,2, Hannu Kautiainen3,4, Pia Elfving1, Elina Savolainen5, Helena Niinisalo6,7 and Oili Kaipiainen-Seppanen1, 1Department of Medicine, Kuopio University Hospital, Kuopio, Finland, 2Iisalmi Hospital, Iisalmi, Finland, 3Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, 4Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 5Kuopio Municipal Hospital, Kuopio, Finland, 6Suonenjoki Health Center, Suonenjoki, Finland, 7Varkaus Hospital, Varkaus, Finland

    Background/Purpose: Lipolysis is increased in rheumatoid arthritis (RA), and lipid-induced insulin resistance coincides with anabolic resistance. Ability to maintain skeletal muscle mass is impaired in…
  • Abstract Number: 2614 • 2015 ACR/ARHP Annual Meeting

    Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis

    Lance Feller1, Paul Tuttle IV2, Austin M. Dalrymple3, Srikanth Bathula4, Katherine Temprano5, Reema H. Syed6, Rama Bandlamudi7, Kathryn Coulson8, Peri Pepmueller9 and Terry Moore10, 1Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO, 2Saint Louis University, Saint Louis, MO, 3Pediatric Rheumatology, St. Louis University, St. Louis, MO, 4Rheumatology, Saint Louis University, Saint Louis, MO, 5Medicine/Rheumatology, Saint Louis University, St. Louis, MO, 6IM-Rheumatology, Saint Louis University, St. Louis, MO, 7Internal Medicine/Rheumatology, St. Louis Univ Health Sciences, St. Louis, MO, 8Rheumatology/ 213A, St. Louis University, St. Louis, MO, 9Rheumatology, Saint Louis University, St. Louis, MO, 10Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO

    Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
  • Abstract Number: 2615 • 2015 ACR/ARHP Annual Meeting

    Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity

    Elizabeth R. Wahl1,2, Andrew Gross2, Vladimir Chernitskiy2, Patricia P. Katz2 and Jinoos Yazdany3, 1Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, 2Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA

    Background/Purpose: A brief patient-reported measure of physical function, the PROMIS PF-10a, is sensitive to changes in disease activity among patients with rheumatoid arthritis (RA). However,…
  • Abstract Number: 2616 • 2015 ACR/ARHP Annual Meeting

    Study of Anti-Carbamylated Protein Antibody in the Rheumatoid Patients Who Were Clinically Active and Under Treatment with Biological Dmards

    Kazuko Shiozawa1 and Shunichi Shiozawa2, 1Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan, 2Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan

    Background/Purpose: A newly discovered anti-carbamylated protein antibody (anti-CarP) is found prior to disease-onset, associates with the conversion towards arthralgia and with a more severe disease…
  • Abstract Number: 2617 • 2015 ACR/ARHP Annual Meeting

    Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis

    Olga S. Zhukov1, Jonnielyn G. Rivera1, Rania W. Abolhosn1, Robert J. Lagier2, Charles M. Rowland3, Joanna M. Popov1, Kaleb Michaud4 and Stanley J. Naides1, 1Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, 2Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, 3Research Support, Quest Diagnostics Alameda, Alameda, CA, 4Rheumatology & Immunology, University of Nebraska Medical Center and National Data Bank, Omaha, NE

    Background/Purpose: Tissue distribution of the chaperonin 14-3-3η (eta) is limited to synovial tissue and brain. Synovium releases proinflammatory 14-3-3η into synovial fluid and serum in…
  • Abstract Number: 2618 • 2015 ACR/ARHP Annual Meeting

    Methotrexate Dose May Associated with the Frequency of Lymphoproliferative Disorders in Rheumatoid Arthritis

    Hiroaki Dobashi1, Tomohiro Kameda1, Masayuki Inoo2, Ikuko Onishi2, Noriyuki Kurata2, Miharu Izumikawa1, Yohei Takeuchi3, Shusaku Nakashima1, Hiromi Shimada1, Hiroki Ozaki1, Risa Wakiya1 and Norimitsu Kadowaki4, 1Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, 2Utazu hospital, Kagawa, Japan, 3Internal Medicine Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Kagawa University, Kagawa, Japan, 4Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University,, Kagawa, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that is characterized by synovitis and the destruction of articular structures of multiple joints. The goal…
  • Abstract Number: 2619 • 2015 ACR/ARHP Annual Meeting

    Clinical Usefulness of Periodic Detection of Serum 14-3-3η for Predicting Efficacy of Tocilizumab in RA

    Akira Sagawa1, Takuya Isayama2, Makoto Kaneda3, Yuan Gui4, Anthony Marotta5 and Jiro Arai2, 1Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 2Medical and Biological Laboratories Co., Ltd., Ina, Japan, 3MBL Europe, Diegem, Belgium, 4Augurex Life Sciences Corp., North Vancouver, BC, Canada, 51423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada

    Background/Purpose: Serum 14-3-3η is a diagnostic marker for RA. Recent in vitro evidence indicates that it may play a casual role in the pathogenesis of…
  • Abstract Number: 2620 • 2015 ACR/ARHP Annual Meeting

    Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis

    Cristina Regueiro1, Diana Peiteado2, Laura Nuño3, Alejandro Villalba4, Dora Pascual-Salcedo5, Ana Martínez6, Alejandro Balsa4 and Antonio Gonzalez7, 1Instituto Investigacion Sanitaria - Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 2Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, 3Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, 4Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, 5Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, 6Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, 7Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain

    Background/Purpose: Anti-carbamylated protein (anti-CarP) antibodies have been described as a new type of autoantibodies specific of patients with rheumatoid arthritis (RA). They seem useful as…
  • Abstract Number: 2621 • 2015 ACR/ARHP Annual Meeting

    Characteristics of Histopathology and Clinical Course of 19 Cases That Developed a Lymphoproliferative Disease (LPD) during Methotrexate (MTX) Treatment.

    Noriyuki HAYASHI1, Kae HAMAMOTO2, Kouichiro YODA2, Maki YODA2, Shinsuke YAMADA3, Hitoshi GOTO2 and Masaaki INABA2, 1Rheumatology, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Second Department of Internal Medicine, Osaka City University Medical School, Osaka, Japan, 3Rheumatology, Osaka City University Graduate School of Midicine, Osaka, Japan

    Background/Purpose: We examined the clinical features of the cases after discontinuation or decrease of dosage of MTX in the MTX-LPD.Methods: We retrospectively examined a patient…
  • Abstract Number: 2622 • 2015 ACR/ARHP Annual Meeting

    Serum RANKL Levels, Associate with Anti Citrullinated Proteins Antibodies (ACPA) in Early-Untreated Rheumatoid Arthritis and Is Modulated Following Methotrexate

    Aase Haj Hensvold1, Vijay Joshua1, K. Lundberg2, Nadine A. Defranoux3, Saedis Saevarsdottir4 and Anca I Catrina2, 1Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Crescendo Bioscience Inc., South San Francisco, CA, 4Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Receptor Activator of Nuclear factor Kappa-b Ligand (RANKL) is a key regulator of bone metabolism. Anti-citrullinated (cit) protein antibodies (ACPA) have been suggested to…
  • Abstract Number: 2623 • 2015 ACR/ARHP Annual Meeting

    DAS28-ESR and DAS28-CRP Are Not Exchangeable in Daily Clinical Practice: Data from a Large Outpatient Cohort

    Alexander Langer1, Oliver Wiemann2, Stephanie G. Werner2, Felicitas Spiecker3, Sabine Mettler3, Gudrun Lind-Albrecht2 and Hans-Eckhard Langer4, 1Department of Computer Science, RWTH Aachen University, Aachen, Germany, 2RHIO (Rheumatology, Immunology, Osteology), Duesseldorf, Germany, 3RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, 4RHIO (Rheumatology, Immunology, and Osteology), Duesseldorf, Germany

    Background/Purpose: The original DAS28 is based on the erythrocyte sedimentation rate (ESR). An alternative formulation uses the C-reactive protein (CRP). Previous research1,2,3 suggests that in…
  • « Previous Page
  • 1
  • …
  • 1644
  • 1645
  • 1646
  • 1647
  • 1648
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology